Pharmaceutical Contract Manufacturing
Jul 24, 2025
Medtronic Gains CE Mark for MiniMed™ 780G, Begins Onyx™ IDE Study; FDA Clears RIVANNA’s AI Ultrasound Guidance Platform; BD Launches First Clinical Trial with Libertas™ Wearable Injector; Olympus Debuts EU-ME3 Ultrasound Processor in U.S.; Thermo Fisher & Sanofi Expand U.S. Drug Manufacturing Partnership
Medtronic Secured CE Mark Approval for its Minimed™ 780G System, Extending its use to Insulin-Requiring Individuals With Diabetes, Including Children as Young as two Years old, Pregnant Women, and Patients with Type 2 Diabetes On July 21, 2025, Medtronic plc., a global medical technology leader, secured th...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
